North America Viral Vector Manufacturing Market Report and Forecast 2024-2032

The North America viral vector manufacturing market size was valued at USD 4.2 billion in 2023, driven by the increased funding for the development of gene therapies in the region. The market is expected to grow at a CAGR of 7.20% during the forecast period of 2024-2032, with the values likely to rise from USD 4.5 billion in 2024 to USD 7.9 billion by 2032.

Key Takeaways

• In November 2023, Genezen secured USD 18.5 million funding to strengthen its growth trajectory in viral vector manufacturing as well as enable better support to its growing clientele of cell and gene therapy innovators.
• The North America viral vector manufacturing market share is significantly impacted by the rising preference for personalised medicines to tackle chronic diseases.
• In September 2023, Thermo Fisher Scientific expanded the scale of its production at its viral vector manufacturing site worth USD 180 million. Located at Plainville, Massachusetts, the development is projected to boost viral vector production as well as gene therapy production.

In North America, the market is witnessing steady growth driven by the rising demand for gene therapy, vaccines, and other innovative therapeutics to tackle the growing burden of genetic disorders, chronic diseases, and infectious diseases, among others. Viral vectors such as adeno-associated viruses, adenoviruses, and lentiviruses are increasingly employed for gene transfer in gene therapy. The substantial funding for the development of gene therapies is expected to drive the North America viral vector manufacturing market growth in the forecast period. In November 2023, a study published in Nature estimated the annual spending on gene therapy to be USD 20.4 billion in the United States. This rising investment in the biotechnology sector is likely to boost the market size.

One of the significant market trends is the expansion of viral vector development and manufacturing capabilities by the key market players supported by major financial investments. In November 2023, Genezen, a contract development and manufacturing organization (CDMO) in the United States, secured USD 18.5 million in financing led by Ampersand Capital Partners which aimed to strengthen its growth trajectory in viral vector manufacturing as well as enable better support to their cell and gene therapy innovators. Such investments are also poised to foster technological innovation and expansion of manufacturing sites and is expected to meet the growing North America viral vector manufacturing market demand.

In September 2023, Thermo Fisher Scientific expanded the scale of its production at its viral vector manufacturing site worth USD 180 million. Situated at Plainville, Massachusetts, the company intended to make use of its 400,000 square feet viral vector manufacturing unit to boost viral vector production along with gene therapy production simultaneously. These initiatives mark as one of the most impactful North America viral vector manufacturing market trends, expected to help in accelerating the development and commercialization of life-saving therapies which will ultimately impact the market dynamics.

Other factors that influence the market share include the advancement in the healthcare infrastructure, increased research efforts aimed at finding novel therapeutics, and the improvement in regulatory reforms.

North America Viral Vector Manufacturing Market Segmentation

North America viral vector manufacturing market analysis include a detailed breakup of the market based on the following segments:

Market Breakup by Type

• Adenoviral Vectors
• Adeno-associated Viral Vectors
• Lentiviral Vectors
• Retroviral Vectors
• Others

Market Breakup by Disease

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others

Market Breakup by Expression System

• Transient
• Stable

Market Breakup by Application

• Gene Therapy
• Vaccinology
• Therapeutics Development
• Research

Market Breakup by End User

• Pharmaceutical and Biotechnology Companies
• Research Institutes
• CDMO &CROs
• Others

Market Breakup by Countries

• United States of America
• Canada

North America Viral Vector Manufacturing Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Charles River Laboratories
• Finvector
• Kaneka Eurogentec SA
• Merck KGaA
• UniQure NV
• Oxford Biomedica PLC
• AstraZeneca
• Vibalogics
• Sanofi
• F.Hoffmann-La Roche Ltd

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

What was the North America viral vector manufacturing market value in 2023?
The market attained a value of D 4.2 billion in 2023 driven by the driven by the increased funding for the development of gene therapies in the region.

What is the North America viral vector manufacturing market forecast outlook for 2024-2032?
The market is anticipated to grow at a CAGR of 7.16% during the forecast period of 2024-2032, likely to reach a market value of USD 7.9 billion by 2032.

What are the major factors aiding the North America viral vector manufacturing market demand?
The growing prevalence of genetic disorders and the rising healthcare expenditure are fuelling the demand for the market.

What are the major North America viral vector manufacturing market trends?
One of the significant market trends is the expansion of viral vector development and manufacturing capabilities by the key market players. In November 2023, Genezen, a contract development and manufacturing organization (CDMO) in the United States, secured USD 18.5 million in financing. The funding was intended at strengthening its viral vector manufacturing capabilities as well as enabling better support to their cell and gene therapy innovators.

What is the market segmentation based on type?
Based on the type, the market is segmented into adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, and retroviral vectors, among others.

What are the various expression systems available in the market?
Expression systems available in the market include transient and stable.

What is the market breakup by disease?
By disease, the market is divided into cancer, genetic disorders, and infectious diseases, among others.

What are the major end users of viral vector manufacturing?
End users of the market are pharmaceutical and biotechnology companies, research institutes, CDMOs & CROs, among others.

What are the applications of viral vector manufacturing?
Major applications areas of viral vector manufacturing include gene therapy, vaccinology, therapeutics development, and research.

What is the market segmentation by countries?
The market segmentation by countries includes the United States of America and Canada.

Who are the key players involved in the North America viral vector manufacturing market?
The key players in the market are Charles River Laboratories, Finvector, Kaneka Eurogentec SA, Merck KGaA, UniQure NV, Oxford Biomedica PLC, AstraZeneca, Vibalogics, Sanofi, and F. Hoffmann-La Roche Ltd.


This product will be delivered within 5-7 business days.